PCI Pharma Services

What PCI Pharma Services does

PCI Pharma Services is a privately held global Contract Development and Manufacturing Organization (CDMO) founded in 1972 and headquartered in Philadelphia, Pennsylvania. Operating under the legal entity Packaging Coordinators, Inc., the company provides integrated end-to-end drug development, manufacturing, and packaging services to pharmaceutical and biotechnology companies and clinical trial sponsors. Its service portfolio spans sterile and non-sterile drug development, lyophilization, fill-finish, prefilled syringe services, high-potency compound handling, biologics packaging, clinical trial supply chain management, cold chain logistics, commercial packaging, and advanced drug-device combination product assembly.

The company operates 38 GMP-compliant facilities across 30 sites in seven countries (United States, Canada, United Kingdom, Ireland, Germany, Spain, and Australia), supported by more than 8,000 employees. PCI's technology layer centers on the pci|bridge™ digital supply chain platform, which provides clients with real-time visibility into project status, inventory, documentation, and Qualified Person lot release workflows, integrated with DocuSign and Smartsheet. The platform is anchored by validated quality systems including MasterControl, LIMS, and electronic batch records. Supporting offerings include clinicalSMART™ for clinical supply project management, Activ-Blister™ for clinical trial blister packaging, and SpeedSolutions™ for accelerated commercialization.

PCI generates revenue through professional services engagements — long-term development, manufacturing, and packaging contracts with pharma and biotech clients — priced on a quote/contract basis per project. Go-to-market is direct enterprise field sales targeting pharmaceutical and biotech decision-makers, supported by industry conference participation, content marketing, and ESG-driven thought leadership. The company has grown substantially through acquisitions, completing five notable deals between 2017 and 2023 (LSNE, Penn Pharmaceutical Services, Sherpa Clinical Packaging, Pharmaceutical Packaging Professionals, and Millmount Healthcare), and has been recognized with multiple industry awards including 2025 CDMO Leadership Awards for Small Molecule and Biologics categories and consecutive EcoVadis Bronze Medals for sustainability performance.

Name

PCI Pharma Services

Legal name

Packaging Coordinators, Inc.

Website

https://pci.com

Company type

Private

Founded year

1972

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

PCI Pharma Services is a privately held global CDMO providing integrated end-to-end drug development, manufacturing, and packaging services to pharmaceutical and biotechnology companies across 38 GMP facilities in seven countries, supported by the pci|bridge™ digital supply chain platform.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Packaging, Labeling & Serialization (Clinical/Commercial) CDMO (HLAGABAJ)

Keywords

• Contract pharmaceutical manufacturing
• Clinical trial supply services
• Sterile fill-finish
• Pharmaceutical packaging services
• Drug-device combination products

Headquarters

HQ city

Philadelphia, PA

HQ country

United States

HQ region

North America

Offices15 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Supply Chain, Technology or R&D, Marketing or Sales

Revenue model

1. Development & Manufacturing Services: Comprehensive drug development and manufacturing services including sterile and non-sterile manufacturing, lyophilization, fill-finish, prefilled syringe services, high-potency drug development and manufacturing, and oral targeted therapies.
2. Clinical Trial Services: End-to-end clinical trial supply services including temperature controlled packaging, cold chain logistics, clinical storage and distribution, packaging design and development, and returns management.
3. Commercial Packaging Technology: Commercial packaging services for both sterile and non-sterile products including standard and specialty dosage forms, serialization, compliance packaging, and launch support.
4. Advanced Drug Delivery & Drug-Device Combination Products: Specialized services for drug-device combination products including prefilled syringes, advanced delivery systems, and combination product assembly and packaging.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

PCI Pharma Services is a global contract development and manufacturing organization (CDMO) providing integrated end-to-end drug development, manufacturing, and packaging solutions for pharmaceutical and biotech clients. Services span sterile and non-sterile development and manufacturing, clinical trial supply chain services, commercial packaging technology, advanced drug delivery, and drug-device combination products, delivered through 38 GMP facilities across 7 countries.

Product overview

PCI Pharma Services is a global Contract Development and Manufacturing Organization (CDMO) providing integrated end-to-end drug development, manufacturing, and packaging solutions. The company operates two primary service categories: Sterile Services and Non-Sterile Services, each encompassing Development & Manufacturing, Clinical Trial Services, and Commercial Packaging Technology. The portfolio is anchored by the pci | bridge™ digital supply chain management platform, which provides clients with real-time visibility and integrates with DocuSign and Smartsheet. Supporting offerings include clinicalSMART™ for clinical supply project management, Activ-Blister™ Solutions for patient compliance packaging, and SpeedSolutions™ for accelerated commercialization. PCI also employs validated systems including MasterControl and LIMS within its digital quality ecosystem to ensure compliance and operational precision.

Differentiator

Problem solved

Functional benefit

Brands

• clinicalSMART: Clinical supply project management solution for clinical trials
• SpeedSolutions
• pci | bridge
• Activ-Blister

Products and services

• Sterile Services Integrated sterile pharmaceutical CDMO services spanning drug development and manufacturing, clinical trial services, advanced drug delivery, and commercial packaging technology for sterile pharmaceutical products. Capabilities include sterile fill-finish, lyophilization (cycle development, bulk, and fill-finish), prefilled syringe services, complex formulations, and drug-device combination product assembly. Targeted at pharmaceutical and biotech clients requiring sterile manufacturing and packaging for injectable, biologic, and high-potency products.
• Non-Sterile Services Integrated non-sterile pharmaceutical CDMO services spanning drug development and manufacturing, clinical trial services, and commercial packaging technology for non-sterile pharmaceutical products. Targeted at pharmaceutical and biotech clients requiring oral solid dose, topical, and other non-sterile manufacturing and packaging services.
• SpeedSolutions™ Integrated suite of speed-to-market solutions designed to accelerate drug development and commercialization timelines for pharmaceutical and biotech clients. Brings together PCI's capabilities across development, manufacturing, clinical supply, and commercial packaging under a unified accelerated timeline approach.
• pci | bridge™ Digital Supply Chain Platform Client-facing digital supply chain management platform connecting clients to critical operational data with real-time visibility into project status, inventory movement, and documentation workflows across clinical development through commercial launch. Features include customizable KPI dashboards, real-time inventory data, configurable reports, secure document sharing via DocuSign, automated QP lot release workflows, protocol spend tracking, and commercial forecast submission. Sold as part of PCI's CDMO service engagement for pharmaceutical and biotech clients.
• clinicalSMART™ Clinical Supply Project Management Clinical supply project management service solution for tracking and managing clinical trial logistics, packaging, and distribution activities. Targeted at pharmaceutical and biotech sponsors running clinical trials who require integrated supply chain visibility and project coordination.
• Activ-Blister™ Solutions Specialized blister packaging solutions for clinical trials, designed for patient compliance and adherence packaging. Targeted at pharmaceutical and biotech sponsors running clinical trials requiring patient-centric packaging to support medication adherence.

Quantifiable outcome

• More than 90 successful product launches per year
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

Feature4 records

Partnerships

One partnership is on record.

• YpsomedsignificantStrategic or Co-development PartnerPartnership for sustainable drug-device combination products. Ypsomed introduced YpsoMate in NetZero Program, a prefilled autoinjector designed to emit fewer greenhouse gas emissions. PCI collaborates on sustainable packaging solutions for injection devices. PCI helps clients evaluate, test, and launch eco-friendly packaging solutions for drug-device combination products.

Scale indicators9 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Siegfried Holding: Swiss CDMO specializing in API production, oral solid dose drug products, and sterile fill-finish. Comparable to PCI on integrated small-molecule CDMO services and European footprint.
• Recipharm: European-headquartered CDMO offering sterile fill-finish, oral solids, biologics, and advanced delivery services. Closely comparable in scale, sterile focus, and integrated service model.
• Catalent: Global CDMO offering development, manufacturing, and packaging services across sterile injectables, oral solids, and biologics; now owned by Novo Holdings. Directly comparable to PCI in integrated CDMO scope, though larger and more biologics-weighted.
• Aenova: European CDMO with strong capabilities in oral solids, sterile liquids, and packaging for pharma and consumer health. Similar mid-tier scale to PCI with overlapping sterile and packaging capabilities.
• Almac Group: Northern Ireland-headquartered CDMO offering pharmaceutical development, clinical trial supply, commercial manufacturing, and packaging services. Directly comparable to PCI across both sterile and non-sterile service lines.
• WuXi STA (WuXi AppTec): Chinese-headquartered integrated CDMO providing API manufacturing, drug product development, and commercial manufacturing across small molecules and biologics. Comparable to PCI on integrated development-through-commercial scope, though geography-anchored in Asia.
• Samsung Biologics: Large-scale biologics CDMO offering contract manufacturing, development services, and aseptic fill-finish. Directly comparable for the biologics segment of PCI's sterile services portfolio.

Broad incumbents

• Lonza: Swiss-headquartered CDMO leader with deep capabilities in API manufacturing, biologics, cell and gene therapy, and drug product services. Highly comparable integrated offering, materially larger, and a benchmark for PCI's biologics expansion.
• Thermo Fisher Scientific (Patheon): Operates one of the largest global CDMO networks (formerly Patheon) across small molecules, biologics, sterile fill-finish, and clinical supply services. Comparable to PCI across essentially all service lines but with greater scale and parent-company resources.

Others

• Yposomed (as a partner, not peer): Swiss drug-device combination product manufacturer (auto-injectors, pen injectors). Listed as a strategic partner of PCI for sustainable injection devices rather than a direct competitor; included to highlight the drug-device combination adjacency rather than core CDMO competition.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/pciservices

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PCI Pharma Services